FOSUN HEALTH Logo

Breast Cancer Prevention

catalogue

Breast Cancer Prevention

Breast Cancer Prevention

Prevention in breast cancer is mostly about finding the disease at the stage when treatment is simplest, and for a small group of women it also includes measures that reduce the chance of developing it at all.

Screening: what it finds, and when to start

Mammography is the only screening test for breast cancer that has been shown in randomised trials to reduce deaths from the disease, and it works by finding tumours years before they can be felt. Its benefit is largest where it is repeated on schedule, because the comparison with previous images is part of how a mammogram is read.

  • Average risk

    Begin mammography at around 40 and repeat every one to two years. In China, organised screening programmes also cover defined age groups. Where breast tissue is dense, ultrasound is added — a combination that improves detection in exactly the group in which mammography alone is weakest.

  • Moderately increased risk

    A first-degree relative with breast cancer, previous atypical hyperplasia, or previous chest radiotherapy. Imaging begins earlier, intervals are shorter, and the plan is set by a specialist rather than by an age-based programme.

  • High genetic risk

    A known BRCA1, BRCA2 or other high-penetrance mutation. Annual MRI from a young age, usually alternating with mammography, is the standard, and the discussion extends beyond imaging to risk-reducing options.

The interval matters as much as the starting age. A mammogram taken once is a snapshot; mammograms taken on schedule allow the reader to see what has changed, and change is often the earliest sign. If a symptom appears, it is investigated on its own timetable and does not wait for the next screening appointment.

Working out which schedule applies to you

Guidelines organise screening by risk group, so the practical first step is establishing which group you are in. That takes a structured conversation rather than a general recommendation.

Bring these to a risk assessment:

  • Family history across three generations — who was affected, on which side of the family, at what age, and whether there was ovarian cancer or male breast cancer
  • Your own breast history — any previous biopsy, and what it showed, particularly atypical hyperplasia or lobular carcinoma in situ
  • Previous chest radiotherapy — the reason for it, and the age at which it was given
  • Any genetic test results — yours, or those of an affected relative if they are available
  • Breast density from your last mammogram — usually stated in the report, and it determines whether ultrasound is needed

Surveillance for high genetic risk

Where a high-penetrance mutation is confirmed, surveillance is intensified and starts young. The pattern below reflects international practice; the exact ages are set individually with the genetics and breast teams.

  • Annual MRI from the mid-twenties to thirties

    MRI detects tumours in dense, young breast tissue that mammography reads poorly. In carriers it is the primary surveillance method from the age at which the risk begins to rise, determined by the specific gene.

  • Mammography added from around age 30

    Usually alternating with MRI at six-month intervals rather than replacing it. The two tests are complementary in this group, and doing both is what the risk justifies.

  • Ovarian surveillance, and the conversation about surgery

    BRCA mutations raise ovarian cancer risk as well, and surveillance for that is arranged in parallel. The option of risk-reducing surgery is discussed early rather than deferred, because its timing interacts with decisions about childbearing and with the effectiveness of the measures available.

Measures that reduce risk, and who they are for

For most women, the measures below are not applicable or not worth their costs. For a small group at the highest risk they are realistic options, and they should be discussed rather than discovered later.

Measure Who it is considered for What to weigh
Risk-reducing mastectomy Confirmed high-penetrance mutation, or a very strong family history Substantially reduces but does not eliminate risk; irreversible; reconstruction can be performed at the same time
Risk-reducing salpingo-oophorectomy BRCA1 or BRCA2 carriers, after childbearing Reduces ovarian cancer risk, and in premenopausal carriers also reduces breast cancer risk; induces menopause
Endocrine risk-reducing therapy Women at increased risk from atypical hyperplasia, LCIS, or a strong family history Reduces the incidence of hormone receptor-positive breast cancer; requires a multi-year commitment and has menopausal side effects
Intensified imaging alone Increased risk where surgery and drug prevention are not appropriate Finds disease earlier but does not prevent it; a legitimate choice that should not be treated as a refusal of care

These options apply only to defined risk groups. For women at average risk, the appropriate preventive measure is screening on schedule, not surgery or drug prevention.

Lifestyle measures and how much they change

The modifiable factors are limited and their effects are modest compared with age and inherited risk. That is worth saying plainly, because overstating them turns prevention into a burden of blame instead of a set of choices.

  • Alcohol

    Risk rises with the amount consumed and the association is present even at lower intakes. Reducing consumption is one of the clearer modifiable steps available.

  • Weight and activity

    Higher body weight after menopause and physical inactivity are both associated with higher risk. Regular moderate activity is associated with lower risk, largely independent of weight.

  • Hormone therapy decisions

    Prolonged combined hormone therapy is associated with higher risk. Where it is being considered for menopausal symptoms, the duration and the preparation are worth a specific conversation with the prescribing clinician.

Breastfeeding is associated with a modest reduction in risk, and for women who have the choice, it is one of the few reproductive factors that moves in a favourable direction. None of this replaces screening.

What screening can and cannot do

Screening is not infallible, and understanding its limits is part of using it well.

  • What it does well

    It finds cancers earlier, on average, than waiting for symptoms, which means more breast-conserving surgery, less chemotherapy, and better survival in the group screened. It finds in situ disease before it becomes invasive, and it detects tumours in the opposite breast when a patient is already being treated.

  • Where it falls short

    Dense tissue hides tumours; some cancers grow quickly between intervals and are found despite a recent normal test; and some findings turn out to be benign, leading to further tests and anxiety. Interval cancers and false positives are known limitations, not evidence that screening does not work.

  • A normal mammogram after a change

    A new lump or skin change needs assessment even if a recent mammogram was normal. Imaging is a test, not a certificate, and symptoms take precedence over a previous result.

  • Screening is not for diagnosis

    Diagnostic imaging for a symptom is a separate pathway with different protocols and reporting. Mixing the two leads to delays, which is why a symptom should be referred to a diagnostic clinic rather than to the next screening round.

These distinctions are set out in more detail, alongside what each test can answer, in how breast cancer is diagnosed.

Building your own plan

A surveillance plan is a schedule with a reason behind each element, and it should be written down so that it can be followed wherever you are. The elements below cover what a plan typically contains.

  • Establish your risk group, once

    Family history, personal breast history, genetic results if any, and breast density. This is done once and revisited when something changes, rather than decided afresh at each appointment.

  • Set the modality and the interval

    Mammography alone for most women; mammography plus ultrasound where tissue is dense; MRI-led surveillance for high genetic risk. The interval follows from the risk group and is not adjusted by anxiety or by convenience.

  • Decide what happens if something is found

    Know in advance where a suspicious finding would be assessed and by whom. Being referred promptly is a property of the plan, not luck.

  • Keep the images

    Retain every mammogram, ultrasound and MRI in digital form. Comparison with previous studies is one of the most informative things a reader does, and images left behind when moving between hospitals cannot be compared. For women who have already been treated for breast cancer, surveillance has an additional purpose — detecting recurrence — and the schedule is different. That is covered in the practical questions page, alongside follow-up arrangements after treatment abroad. The factors behind the risk estimates used above are set out in causes and risk factors.

Frequently Asked Questions

At what age should I start having mammograms?

For average risk, around age 40, repeated every one to two years — this is the range used by major guideline bodies and reflected in China's organised programmes. If you have a first-degree relative with breast cancer, previous chest radiotherapy, a confirmed genetic mutation, or previous atypical hyperplasia, you should start earlier and the schedule should be set individually. Age alone is not the right basis for the decision in those groups.

Do I need ultrasound as well as a mammogram?

If your breast tissue is dense, yes. Density reduces the sensitivity of mammography because both glandular tissue and tumour appear white; adding ultrasound improves detection in precisely that situation. Density is reported with your mammogram, so the answer is usually available in a report you already have. Many centres in China combine the two as standard for this reason.

I found a lump but my last mammogram was normal. What now?

Have the lump assessed. A normal mammogram does not exclude a cancer that has appeared since it was taken, and it does not override a physical finding. The correct next step is diagnostic imaging of that specific area — usually ultrasound, sometimes MRI — with biopsy if the imaging is suspicious. Waiting for the next scheduled screening round is not appropriate.

Is there anything I can take to prevent breast cancer?

Only for a defined group at increased risk, where endocrine risk-reducing therapy can lower the incidence of hormone receptor-positive breast cancer. It requires a multi-year commitment and carries menopausal side effects, so it is a genuine trade-off rather than a simple benefit. For women at average risk, there is no drug prevention that is worth its costs, and the effective measure is screening on schedule.

Patient Stories

Stories from our breast cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Get a surveillance plan in writing

Send your family history, previous imaging reports, breast density from your last mammogram and any genetic results. Our breast team will return a written risk assessment and a recommended screening schedule within 48 hours of the file being complete — including an opinion on whether your current plan is adequate.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*